DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives

I n mPC cases with somatic and germline BRCA mutations, perform germline evaluation for all related family members after genetic counseling, so to predict early cancer screening. The same germline evaluation is suggested in cases with high risk nmPC with 2 or more relatives with history of mammary, ovarian or prostate neoplasms, or history of prostate cancer at early (<55 years) development. Consider a PARP inhibitor tailored therapy in cases with mCRPC progressing after first line therapy, showing somatic and/or germline BRCA2 mutation